About Us - Leadership
Although Cao Pharmaceuticals is a startup company, it has a rich history. Prior to forming Cao Pharmaceuticals, our staff were principally responsible for CPT drug development at the Christus Stehlin Foundation for Cancer Research. Here they were at the forefront of CPT drug development and have acquired a vast amount of knowledge and experience with these CPT drugs. With this knowledge they feel they now have the keys to unlocking the full potential of "Using natures best anti-cancer compound and making man's best cancer drugs".
|
CEO
Zhisong Cao, Ph.D.: CEO and Chief Chemist: Over twenty years of experience in CPT (camptothecin) chemistry, inventor and co-holder of 17 CPT related patents, and licensing of CPT compounds. Prior to founding Cao Pharmaceuticals, he served as the Associate Laboratory Director and Chief Chemist for the Stehlin Foundation for Cancer Research. In this capacity he was responsible for all Chemistry R&D, strategic direction of drug development, patenting and licensing. In his twenty years of being solely involved in CPT drugs, he has synthesized hundreds of CPT drugs using thousands of drug intermediates. This rare amount of knowledge provides Cao Pharmaceuticals Inc. a distinct advantage in the design and synthesis of pipeline candidates of these drugs .
Clinical Director/V.P. of Operations
Doug Coil,: Over thirty years of experience in oncology drug development. His background covers a broad range of the drug development process, including budgeting, contract negotiations and business development. He was the Clinical Director at the Stehlin Foundation for Cancer Research where he lead both the pre-clinical drug development program and the clinical program including protocol development, FDA IND submissions, and several FDA Phase I and Phase II studies involving CPT (camptothecin) based drugs. Cao Pharmaceuticals has leveraged this experience to receive FDA approval for the current and ongoing Phase I study of CZ48, the planning of several Phase II studies of CZ48, and to guide from a clinical perspective the development of the pipeline drugs.
Chief Pharmacologist
Yang Wang,: Ph.D. Prior to joining Cao Pharmaceuticals, she had over twenty years of experience in CPT (camptothecin) related drug development as a Research Scientist at the Stehlin Foundation for Cancer Research. At Cao Pharmaceuticals she oversees both the pre-clinical testing and formulation development of the pipeline drugs, and the clinical pharmacokinetics, pharmacodynamics, and biomodeling studies of the phase I clinical trial of CZ48, a camptothecin derivative.
V.P. Investor Relations
Chris Wood: Heads our Investor Relations with over 30 years of finance, accounting, information technology, management, and business ownership experience. He is currently coordinating investor relations and securing funding to complete the CZ48 FDA Phase I trial and begin the FDA Phase II trials.
Zhisong Cao, Ph.D.: CEO and Chief Chemist: Over twenty years of experience in CPT (camptothecin) chemistry, inventor and co-holder of 17 CPT related patents, and licensing of CPT compounds. Prior to founding Cao Pharmaceuticals, he served as the Associate Laboratory Director and Chief Chemist for the Stehlin Foundation for Cancer Research. In this capacity he was responsible for all Chemistry R&D, strategic direction of drug development, patenting and licensing. In his twenty years of being solely involved in CPT drugs, he has synthesized hundreds of CPT drugs using thousands of drug intermediates. This rare amount of knowledge provides Cao Pharmaceuticals Inc. a distinct advantage in the design and synthesis of pipeline candidates of these drugs .
Clinical Director/V.P. of Operations
Doug Coil,: Over thirty years of experience in oncology drug development. His background covers a broad range of the drug development process, including budgeting, contract negotiations and business development. He was the Clinical Director at the Stehlin Foundation for Cancer Research where he lead both the pre-clinical drug development program and the clinical program including protocol development, FDA IND submissions, and several FDA Phase I and Phase II studies involving CPT (camptothecin) based drugs. Cao Pharmaceuticals has leveraged this experience to receive FDA approval for the current and ongoing Phase I study of CZ48, the planning of several Phase II studies of CZ48, and to guide from a clinical perspective the development of the pipeline drugs.
Chief Pharmacologist
Yang Wang,: Ph.D. Prior to joining Cao Pharmaceuticals, she had over twenty years of experience in CPT (camptothecin) related drug development as a Research Scientist at the Stehlin Foundation for Cancer Research. At Cao Pharmaceuticals she oversees both the pre-clinical testing and formulation development of the pipeline drugs, and the clinical pharmacokinetics, pharmacodynamics, and biomodeling studies of the phase I clinical trial of CZ48, a camptothecin derivative.
V.P. Investor Relations
Chris Wood: Heads our Investor Relations with over 30 years of finance, accounting, information technology, management, and business ownership experience. He is currently coordinating investor relations and securing funding to complete the CZ48 FDA Phase I trial and begin the FDA Phase II trials.